AdvaMed Tags China-Made Device Knock Offs As Concern At Federal Commission Hearing
This article was originally published in The Gray Sheet
U.S. device companies dealing in Asia worry about Chinese firms stealing American manufacturers’ intellectual property, then selling knock-offs of American devices that look similar, but are not as safe, AdvaMed’s executive VP of global strategies Ralph Ives told a U.S.-China trade commission April 3.
You may also be interested in...
In an executive memorandum, President Trump formally pulled the US out of the Trans-Pacific Partnership (TPP) trade agreement that had been negotiated with 11 other countries and strongly supported by the device industry. Medtech industry groups tried to put a good face on things, saying they look forward to working with the new administration on bilaterial agreements to further open markets in Asia and elsewhere.
The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.
China’s county-level public hospitals may be required to participate in provincial bidding to purchase medical devices like stents and pacemakers, putting pricing pressure on multinationals such as Boston Scientific, Medtronic and Abbott Laboratories and domestic manufacturers like MicroPort Scientific.